Endocannabinoid system and CNR1 gene polymorphisms in schizophrenia and addictive disorders

Actas Espanolas de Psiquiatria

Volumn 35, Issue 2, 2007, Pages 122-129

  Martinez Gras I ^a,d   Hoecnika, J ^b   Perez Hernandez E ^c   Rodriguez Jimenez R ^b   Ponce, G ^b   Jimenez Arriero M A ^b   Ramos Atance, J ^c   Palomo, T ^b   Rubio, G ^a  

^a Servicios de Salud Mental de Retiro   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d Retiro Mental Health Service   (Spain)

Author keywords

Addictions; Cannabis; CNR1; Schizophrenia

Indexed keywords

CANNABINOID 1 RECEPTOR; ENDOCANNABINOID;

ADDICTION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; HUMAN; REVIEW; SCHIZOPHRENIA;

BEHAVIOR, ADDICTIVE; ENDOCANNABINOIDS; GENE EXPRESSION; HUMANS; POLYMORPHISM, GENETIC; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA;

EID: 34248225784     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Mechoulam R, Devane WA, Glaser R. Cannabinoid geometry and biological activity. In: Bartke A, Murphy LL, editors. Marihuana/cannabinoids: neurobiology and neurophysiology. Biochemistry and physiology of substance abuse. Vol IV. Boca Ratón: CRC Press, 1992; p. 1-34.
2. Jarbe TUC, Mathis DA. Dissociative and discriminative stimulus functions of cannabinoids/cannabimimetics. In: Bartke A, Murphy LL, editors. Marihuana/cannabinoids: neurobiology and neurophysiology. Biochemistry and physiology of substance abuse. Vol IV. Boca Ratón: CRC Press, 1992; p. 459-524.
3. 9)-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998;95:8268-73.
4. 9)- tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes. Pharmacol 1983;26:12-9.
5. Makriyannis A. The role of cell membranes in cannabinoid activity. In: Pertwee RG, editor. Cannabinoid receptors. London: Academic Press, 1995; p. 87-115.
6. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13.
7. Felder CC, Briley EM, Axelrod J, Simpsom JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993;90:7656-60.
8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabonoid receptor. Science 1992;258:1046-949.
10. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz NE, et al. Identification of an endogenous 2-monoglyceride, present in canine, gut, that binds to cannabinoid receptors. Biochem. Pharmacol 1995;50:83-90.
11. Sugiura T, Kondo S, Sukagawa A, Nakane A, Shinoda A, Itoh K, et al. 2-araquidonylglycerol: a possible endogenous cannabinoid ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
12. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. Arachidonyl glyceryl ether an endogenous agonist of the cannabinoid CB1 receptor. PNAS 2001;98:3662-5.
13. Di Marzo V, Melck DM, Bisogno T, de Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998;2:521-8.
14. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther 1997;74:129-80.
15. Howlett AC, Mukhopadhyay S, Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonylglycerol. Chem Phys Lipids 2000;108:53-70.
16. Pertwee RG. The central neurophamacology of psychotropic cannabinoids. In: Balfour OKJ, editor. Psychotropic drugs of abuse. New York: Pergamon Press, 1990; p. 335-429.
17. Vela G, Ruiz Gayo M, Fuentes JA. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacol 1995;34:665-8.
18. Thorat SN, Bhargava HN. Evidence for a bidirectional cross-to-lerance between morphine and D 9-tetrahydrocannabinol in mice. Eur J Pharmacol 1994;260:5-13.
19. Manzanares J, Corchero J, Romero J, Fernández Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and Biochemical interactions between opiods and cannabinoids. Trends Pharmacol Sci 1999;20:287-94.
20. Sakurai Y, Ohta H, Shimazoe T, Cataoka Y, Fujiwara M. Delta-9-tetrahydrocannabinol elicet ipsilateral circling behaviour in rats with unilateral nigral lesions. Life Sci 1985;37:2181-5.
21. Kramer J, Ben-David M. Prolactin suppression by (-) D 9-tetrahydrocannabinol (THC): involvement of serotoninergic and dopaminergic pathways. Endocrinology 1978;103:452-8.
22. Shen M, Piser TM, Sheybold US, Thayer SA. Cannabinoid receptor agonist inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996;16:4322-34.
23. 9-tetrahydrocannabinol acts a partial agonist to modulate glutamatergic synaptic transmission between rat hyppocampal neurons in culture. Mol Pharmacol 1999;55:8-13.
24. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998;54:459-62.
25. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997;388:773-8.
26. 9-tetrahydrocannabinol in rats. Eur J Pharmacol 1971;14:89-92.
27. Rodríguez de Fonseca FA, Fernández-Ruiz TI, Eldridge TC, Steger RW, Bartke A, Murphy LL. Effects of the delta-9-tetrahydrocannabinol on the adrenal medullary function: evidence of an acute effect and development of tolerance in chronic treatments. Pharmacol Biochem Behav 1991;40:593-8.
28. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL Delta-9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 1990;102:156-62.
29. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopaminc transmission by a common μ, opioid receptor mechanism. Science 1997;276:2048-50.
30. Herkenham M, Lynnn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat brain. Brain Res 1991;548:267-74.
31. Herkenham M, Lynnn AB, Jhonson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991b;11:563-83.
32. Breivogel CS, Sim CJ, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 1997;282:1632-42.
33. Bisogno T, Berrendero F, Ambrosino G, Cebeira R, Ramos JA, Fernández-Ruiz J, et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999;256:377-80.
34. Felder C, Glass M. Cannabinoid receptors and their endogenous agonists. Ann Rev Pharmacol Toxicol 1993;38:179-200.
35. Hoehe MR, Caenazzo L, Martínez MM, Hsieh WY, Modi VS, Gershon ES, et al. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol 1991;3:880-5.
36. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, et al. Human cannabinoid receptor 1:5'exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004;1-16.
37. rd ed. Baltimore: Williams and Wilkins, 1997; p.199-206.
38. Van Os J, Back M, Hanssen M, Bijl RV, de Graff R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319-27.
39. Arseneault LL, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325:1212-3.
40. Arseneault L L, Cannon M, Witton BS, Murray RB. Casual association between cannabis and psychosis:examination of the evidence. Br J Psychiatry 2004;184:110-7.
41. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002;325:1195-8.
42. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002;325:1199-201.
43. Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescent later hospitalized for schizophrenia. Am J Med Genetics 2002;114:949-55.
44. Fergusson DM, Norwood U, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2002;33:15-21.
45. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004;161:501-6.
46. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction 2004;99:425-30.
47. Rey JM, Martin A, Krabman P. Is the party over? Cannabis and juvenile psychiatric disorders: the past 10 years. J Am Acad Child Adolesc Psychistry 2004;43:1194-204.
48. Andreasson S, Allebeck P, Engstrom A, Reigberg U. Cannabis and schizphrenia. A longitudinal study of Swedish conscripts. Lancet 1987;26:1483-6.
49. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and no users of cannabis. A longitudinal study in Stockholm county. Acta Psychiat Scand 1989;79:505-10.
50. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001;178:116-22.
51. Gardner EL, Lowinson JH. Marijuana's interaction with brain reward system: update 1991. Pharmacol Biochem Behav 1999;40:571-80.
52. McKena PJ. Pathology, phenomenology and the dopamine hypothesis of schizophrenia. Br J Psychiatry 1987;151:288-301.
53. Mailleux, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptors in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992;48:655-68.
54. Cao Q, Martinez M, Zhang J, Sanders AR, Badner JA, Crauchick A. Suggestive evidence for a Schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 1997;43:1-8.
55. Caenazzo L, Hoehe MR, Hsieh WT, Berrettini, WH Bonner TI, Gerson ES. Hindlll identifies a two allele DMA polymorphism of the human cannabinoid receptor gene (CNR). Nucl Acids Res 1991;19:4798.
56. Dawson E. Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatric Genet 1995;5:850(S50-1).
57. Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatric Genet 2000;10:149-51.
58. Leroy S, Griffon N, Bourdel MG, Olié JO, Poirier MF, Krebs MO. Schizophrenia and cannabinoid receptor type 1 (CB1): association study using a single base polymorphism in coding exon. Am J Med Genet 2001;105:749-52.
59. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002;7:515-8.
60. Herkenham M, Lynn AB. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990;87:1932-6.
61. Herkenham M, Lynn AB, Jhonson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neuroscience 1991;11:563-83.
62. Matsuda A, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993;327:535-50.
63. Ledent C, Valverde O, Cossu G. Unresponsiveness to cannabinoids, reduced addictive effects of opiates in CB. Receptor knockout mice. Science 1999;283:401-4.
64. Berrendero F, Castane A, Ledent C. Increase of morphine withdrawal in mice lacking A2areceptors and no changes in Cb1/A2a double knockout mice. Eur J Neurosci 2003;17:315-24.
65. Castane A, Valjent E, Ledent C, et al. Lack of CB1 cannabinoid receptors modifies nicotine behavioral responses, but no nicotine abstinence. Neuropharmacology 2002;43:857-67.
66. Arnone M, Maruani J, Chaperon F. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1997;132:104-6.
67. Comings DE, Muhleman D, Gade R, Jhonson P, Verde R, Saucier G. Cannabinoid receptor gene (CNR1): association with iv drug use. Mol Psychiatry 1997;2:161-8.
68. Jhonson JP, Muhleman D, McMurray J, Gade R, Verde R, Ask M, et al. Association between the cannabinoid receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry 1997;2:169-71.
69. Li T, Liu X, Zhu ZH, Zhao J, Hu X Ball DM, et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000;5:128-30.
70. Covault J, Gelernter J, Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry 2001;6:501-8.
71. Heller D, Schneider U, Seifert J, Cimander KF, Stuhrmann M. The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users. Addict Biol 2001;6:183-7.
72. Schmidt LG, Samochoviec J, Finch U. Association of cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 2002;65:221-4.